An increased risk of HZ has been observed in RA patients treated with JAKi or certain biologic DMARDs (bDMARDs), such as monoclonal anti-tumor necrosis factor (TNF) antibodies and B cell targeted therapy, compared with those treated with conventional DMARDs13. This evidence concerns the gene TNF and rheumatoid arthritis.